인쇄하기
취소
|
As a chain of rebate issues have hit the industry, multinational pharmaceutical companies were criticized to excessively behave on managing their partner companies.
They are known to send out official documents to investigate rebate actions as well as inspecting their co-marketing companies under the Compliance Program(CP) on their own.
The problem is they are creating the atmosphere while ...